List All Gynecologic Cancer Trials

Gynecologic Cancer

 

Chemotherapy + Pelvic Radiation for High-Risk Early-Stage Cervical Cancer (GOG/ RTOG 0724)
Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy with or Without Adjuvant Chemotherapy in High-Risk Patients with Early-Stage Cervical Carcinoma Following Radical Hysterectomy

Investigator: Heidi J. Gray, MD;   Conditions: Cervical Cancer;    Status: Open;   Study ID: NCT00980954

Radiation Therapy Stage I or Stage II Cervical Cancer Post Surgery (GOG 0263)
Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated With Initial Radical Hysterectomy and Pelvic Lymphadenectomy

Investigator: ;   Conditions: Cervical Cancer;    Status: Recruiting;   Study ID: NCT01101451

MRI- and PET-Predictive-Assay for Cervical Cancer (8118)
MRI- and PET-Predictive-Assay of Treatment Outcome in Cancer of the Cervix

Investigator: Nina Mayr, MD;   Conditions: Cervical Cancer;    Status: Recruiting;   Study ID: NCT01992861

ID-LV305 for Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1
A Phase 1 Safety Study of Intradermal ID-LV305 in Patients With Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1

Investigator: Seth M. Pollack, MD;   Conditions: Breast Cancer, Melanoma, Non-small Cell Lung Cancer, Ovarian Cancer, Sarcoma;    Status: Closed;   Study ID: NCT02122861

Taking Care of Her (9306)
A Pilot Feasibility Study: Taking Care of Her

Investigator: Frances Lewis;   Conditions: Ovarian Cancer;    Status: Recruiting;   Study ID: NCT02401321

Diet and Physical Activity Change After Ovarian and Fallopian Tube Cancer Treatment (GOG0225)
Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Investigator: Heidi Gray, MD;   Conditions: Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cancer;    Status: Recruiting;   Study ID: NCT00719303

Trametinib for Recurrent Ovarian or Peritoneal Cavity Cancer (GOG281)
Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer

Investigator: Heidi Gray, MD;   Conditions: Ovarian Cancer, Ovarian Carcinoma, Peritoneal Carcinoma;    Status: Recruiting;   Study ID: NCT02101788

Olaparib or the Combination of Cediranib and Olaparib to Standard Chemotherapy for Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (NRG-GY004)
A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women with Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Investigator: Heidi Gray, MD;   Conditions: Fallopian Cancer; Ovarian Cancer; Peritoneal Cancer;    Status: Recruiting;   Study ID: NCT02446600

Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard Chemotherapy for Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (NRG-GY005)
A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women with Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)

Investigator: Heidi Gray, MD;   Conditions: Endometrial Cancer; Fallopian Cancer; Ovarian Cancer; Peritoneal Cancer;    Status: Recruiting;   Study ID: NCT02502266